The Use of Faster Acting Aspart in Type 1 Diabetes Patients

The Use of Faster Acting Aspart in Type 1 Diabetes Patients: Multi-centre Real-world Experience

Data on switching from traditional mealtime insulins to fast-acting insulin aspart (Fiasp) in routine clinical practice are sparse. The aim was to evaluate the efficacy and safety of switching from traditional mealtime insulin to Fiasp in a "real-world" clinical practice setting in people with type 1 diabetes in Belgium.

The primary endpoint was the evolution of time in range (TIR, 70-180 mg/dl) at 6 and 12 months. Secondary endpoints included change in HbA1c, BMI, insulin doses, time below range (T<70 and T<54 mg/dl) and time above range (T>180 and T>250 mg/dl).

Retrospective analysis Two-center study

Inclusion Criteria:

• Type 1 diabetes patients
• Duration of diabetes > 2 years
• Using CGM for > 6 months

Exclusion Criteria:

• Using SMBG
• Pregnancy
• Using glucocorticoids or immunosuppressive agents
• Active oncological problem